BV-CHEP

BV-CHEP is an investigational combination chemotherapy regimen consisting of the antibody-drug conjugate brentuximab vedotin (Adcetris) and a chemotherapy backbone of cyclophosphamide, doxorubicin, etoposide, and prednisone (CHEP). Developed by the UNC Lineberger Comprehensive Cancer Center, this regimen is primarily evaluated for the treatment of aggressive adult T-cell leukemia/lymphoma (ATLL). Brentuximab vedotin targets CD30-expressing cancer cells to deliver the cytotoxic microtubule-disrupting agent monomethyl auristatin E (MMAE). The CHEP components provide multi-modal cytotoxic activity: cyclophosphamide acts as a DNA alkylating agent, doxorubicin as a DNA intercalator and topoisomerase II inhibitor, etoposide as a topoisomerase II inhibitor, and prednisone as a lympholytic corticosteroid. The regimen is administered in 21-day cycles and aims to improve remission rates in ATLL, a rare and often treatment-resistant malignancy.

Other names

Brentuximab Vedotin With Cyclophosphamide, Doxorubicin, Etoposide, and PrednisoneCHEP-UNC Lineberger Comprehensive Cancer Center-adult T-cell leukemia/lymphoma